COPENHAGEN, Denmark & BOSTON, August 15, 2023 Visiopharm and Boston Cell Standards today announced a partnership to develop a joint technology solution that enables labs to meet key provisions of regulatory changes proposed in a groundbreaking editorial recently published in Archives of Pathology & Laboratory Medicine.
Partnership to unify spatial staining and imaging with A.I. analysis technologies in end-to-end solution for researchers studying cancer and other diseases. Lunaphore, a Swiss life sciences company
Partnership to improve clinical decision making for breast and colon cancer care Proscia, a leader in digital and computational pathology solutions, and Visiopharm, a world leader in AI-driven precision
Visiopharm, a leader in AI-based digital pathology, has begun its partnership with the Region of Southern Denmark, to supply the network of four hospitals with